GlassScriptPhysician profile
Tomas C Hernandez
NPI 1285978544
$5,362.88
in general payments reported to CMS, 2019-2025
26 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 97% of Pediatrics, Critical Care providers received nationally (typical 2025 total: $80.91).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $1,058 · 2023: $1,238 · 2024: $1,338 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.42 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,282.01 | 2022-2025 | |
| Ucb, INC. | $1,178.65 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $604.66 | 2022-2025 | |
| Neurelis, INC. | $455.34 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $247.09 | 2022-2025 | |
| Eisai INC. | $198.08 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $160.38 | 2022-2024 | Qelbree, Qelbree |
| Sumitomo Pharma America, INC. | $147.83 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $146.28 | 2023-2025 | Daybue |
| Immedica Pharma US, INC. | $143.21 | 2023-2024 | |
| Biogen, INC. | $137.74 | 2021-2025 | Spinraza |
| Argenx US, INC. | $110.67 | 2022-2023 | Vyvgart |
| Catalyst Pharmaceuticals, INC. | $74.09 | 2023-2024 | Fycompa |
| Teva Pharmaceuticals USA, INC. | $60.83 | 2021-2023 | Ajovy |
| Ipsen Biopharmaceuticals, INC | $56.95 | 2024-2025 | Dysport |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $53.94 | 2021 | |
| Cranial Technologies, INC | $49.02 | 2024-2025 | Doc Band |
| Alexion Pharmaceuticals, INC. | $43.99 | 2022-2025 | |
| Sarepta Therapeutics, INC. | $42.88 | 2021-2024 | Elevidys |
| Philips North America LLC | $41.18 | 2025 | Vest Therapy Und |
| Genentech USA, INC. | $24.53 | 2022 | |
| Ns Pharma, INC. | $22.38 | 2025 | Viltepso |
| Zogenix INC. | $21.16 | 2021 | |
| Pyros Pharmaceuticals, INC. | $21.07 | 2024 | Vigpoder |
| Ironshore Pharmaceuticals INC. | $19.82 | 2024 | |
| Merz Pharmaceuticals, LLC | $19.10 | 2025 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.